Kuhlman J E, Teigen C, Ren H, Hruban R H, Hutchins G M, Fishman E K
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD.
Radiology. 1990 Oct;177(1):121-5. doi: 10.1148/radiology.177.1.2399310.
The computed tomographic (CT) chest scans of 11 patients who developed respiratory or constitutional symptoms while receiving amiodarone therapy were reviewed. CT findings indicative of significant amiodarone exposure included (a) high-attenuation parenchymal-pleural lesions in eight of the 11 patients (73%), and (b) increased liver and/or spleen attenuation in 10 of the 11 patients (91%). Nonspecific pulmonary infiltrates were identified in nine of the 11 patients (82%). Four patients had interstitial infiltrates, four had mixed alveolar and interstitial disease, and one had a conglomerate mass. CT findings of high-attenuation parenchymal-pleural abnormalities are thought to be related to the iodinated chemistry of the drug and its prolonged half-life within the lung. These unique properties of the drug and the use of CT to discriminate attenuation levels provide a means of identifying patients with significant pulmonary accumulation of amiodarone.
对11例在接受胺碘酮治疗期间出现呼吸道或全身症状的患者的胸部计算机断层扫描(CT)进行了回顾。提示胺碘酮大量暴露的CT表现包括:(a)11例患者中有8例(73%)出现高衰减实质性-胸膜病变;(b)11例患者中有10例(91%)肝脏和/或脾脏衰减增加。11例患者中有9例(82%)发现非特异性肺部浸润。4例患者出现间质性浸润,4例患者出现肺泡和间质性混合疾病,1例患者出现团块。高衰减实质性-胸膜异常的CT表现被认为与药物的碘化化学性质及其在肺内的长半衰期有关。药物的这些独特性质以及利用CT区分衰减水平提供了一种识别胺碘酮在肺部大量蓄积患者的方法。